[1]左俊荣.特发性膜性肾病的诊断及治疗研究[J].医学信息,2021,34(11):54-56.[doi:10.3969/j.issn.1006-1959.2021.11.016]
　ZUO Jun-rong.Research on the Diagnosis and Treatment of Idiopathic Membranous Nephropathy[J].Medical Information,2021,34(11):54-56.[doi:10.3969/j.issn.1006-1959.2021.11.016]
点击复制

特发性膜性肾病的诊断及治疗研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年11期
页码:
54-56
栏目:
综述
出版日期:
2021-06-01

文章信息/Info

Title:
Research on the Diagnosis and Treatment of Idiopathic Membranous Nephropathy
文章编号:
1006-1959（2021）11-0054-03
作者:
左俊荣
（天津市津南医院内科，天津 300350）
Author(s):
ZUO Jun-rong
(Department of Internal Medicine,Tianjin Jinnan Hospital,Tianjin 300350,China)
关键词:
特发性膜性肾病; 肾小球滤过率; 蛋白尿
Keywords:
Idiopathic membranous nephropathy; Glomerular filtration rate; Proteinuria
分类号:
R692.3
DOI:
10.3969/j.issn.1006-1959.2021.11.016
文献标志码:
A
摘要:
特发性膜性肾病是膜性肾病的一种，临床多以中老年男性常见。该疾病具有发病缓慢，多以水肿为首表现，以大量蛋白尿为主要临床表现。目前，关于特发性膜性肾病发病机制尚未完全明确，早诊断、早治疗是改善患者的有效措施。本文就特发性膜性肾病诊断、治疗研究作一综述，以期为临床特发性膜性肾病诊断和治疗提供一定参考依据。
Abstract:
Idiopathic membranous nephropathy is a kind of membranous nephropathy, which is mostly common in middle-aged and elderly men.The disease has a slow onset, mostly with edema as the first manifestation, and a large amount of proteinuria as the main clinical manifestation.At present, the pathogenesis of idiopathic membranous nephropathy is not completely clear. Early diagnosis and early treatment are effective measures to improve patients.This article reviews the research on the diagnosis and treatment of idiopathic membranous nephropathy, hoping to provide a certain reference basis for the diagnosis and treatment of clinical idiopathic membranous nephropathy.

参考文献/References:

[1]Bobkova LN,Kakhsurueva PA,Stavrovskaya EV.Idiopathic membranous nephropathy:Evolution in understanding the problem[J].Ter Arkh,2016,88(6):89-94. [2]Li J,Chen B,Gao C,et al.Clinical and pathological features of idiopathic membranous nephropathy with focal segmental sclerosis[J].BMC Nephrol,2019,20(1):467. [3]Liu W,Gao C,Dai H,et al.Immunological Pathogenesis of Membranous Nephropathy: Focus on PLA2R1 and Its Role[J].Front Immunol,2019(10):1809. [4]管音,李航,段琳,等.血清抗PLA2R抗体和肾小球IgG4联合检测在膜性肾病诊断中的应用[J].中华肾脏病杂志,2015,31(3):198-202. [5]刘莎莎,张丽,李素华,等.血清抗磷脂酶A2受体抗体在特发性膜性肾病诊断中意义[J].中华实用诊断与治疗杂志,2016,30(4):405-406. [6]李彬.PLA2R 抗体和IgG4诊断特发性膜性肾病的临床意义[D].郑州大学,2017. [7]詹富国,吴秀风,陈惠娟,等.三种实验室指标在膜性肾病中的诊断价值[J].中国卫生标准管理,2017,8(19):124-126. [8]高燕,王倩,李林倩,等.老年特发性膜性肾病患者血清抗PLA2R抗体及IgG亚型检测的临床意义[J].临床荟萃,2018,33(10):867-872. [9]Lu W,Gong S,Li J,et al.Clinicopathological features and prognosis in patients with idiopathic membranous nephropathy with hypertension[J].Exp Ther Med,2020,19(4):2615-2621. [10]夏薇青,裴华颖,李绍梅,等.改良Ponticelli方案治疗特发性膜性肾病的临床研究[J].中华内科杂志,2016,63(3):181-185. [11]向代军,王成彬,马骏龙,等.血清C反应蛋白、纤维蛋白原与原发性肾病综合征相关分析[J].解放军医学院学报,2015(2):124-125,136. [12]Ronco P,Debiec H.Pathophysiological advances in membranous nephropathy:time for a shift in patient’s care[J].Lancet,2015,385(9981):1983-1992. [13]孙晓莉.来氟米特治疗膜性肾病临床效果分析[J].基层医学论坛,2016,20(19):2746-2747. [14]蔡青,刘殿强,周珍,等.环磷酰胺联合糖皮质激素治疗特发性膜性肾病的临床疗效分析[J].临床医学工程,2014,21(11):1445-1446． [15]郭晓姣.特发性膜性肾病不同治疗方案的临床疗效比较[D].山西医科大学,2019. [16]Fervenza FC,Appel GB,Barbour SJ,et al.Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy[J].New England Journal of Medicine,2019,381(1):36-46. [17]李瑞莲,陈文倩,张丹,等.154例肾病综合征患者环孢素A血药浓度监测及其对疗效、安全性的影响分析[J].中国药房,2018,29(20):2827-2831. [18]张健,李冀军,宋岩.小剂量环孢素联合小剂量激素治疗膜性肾病的疗效观察[J].临床肾脏病杂志,2017,17(11):671-675. [19]邓薇,王利民,黄远莲,等.霉酚酸酯联合他克莫司治疗激素抵抗型难治性肾病综合征分析[J].世界临床医学,2019,13(1):64-65. [20]元晓敏.霉酚酚酸酯联合糖皮质激素与环磷酰胺联合糖皮质激素治疗急进性肾炎治疗效果观察及预防患者感染的相关研究[J].黑龙江中医药,2019,48(6):339-340. [21]邹佩美,李航,蔡建芳,等.利妥昔单抗在特发性膜性肾病中的治疗[J].中国医学科学杂志(英文版),2018,33(1):9-19. [22]Fervenza FC,Appel GB,Barbour SJ,et al.Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy[J].N Engl J Med,2019,381(1):36-46. [23]徐军,黄莉,牟洪宾.利妥昔单抗辅助小剂量甲泼尼龙对特发性膜性肾病外周血VDBP,Th17/Treg水平的影响[J].中国临床研究,2020,33(11):26-30. [24]El-Husseini A,Saxon D,Jennings S,et al.Idiopathic membranous nephropathy:diagnostic and therapeutic challenges[J].American Journal of Nephrology,2016,43(2):65-70. [25]朱辟疆,刁金囡.慢性肾脏病中医药治疗应重视清利湿热、活血化瘀药物的应用[J].中国中西医结合肾病杂志,2016,17(10):908-909. [26]刘朝业,胡军福,张威英,等.温肾通络法用于特发性膜性肾病的治疗[J].国际中医中药杂志,2019,41(3):229-233. [27]蔡朕,汪蕾,段昱方,等.参芪地黄汤对气阴两虚型特发性膜性肾病的疗效观察[J].中国医刊,2016,51(1):91-94．

相似文献/References:

[1]黄秉文.中美两种2型糖尿病肾病诊断标准中疾病进展及预后因素对比[J].医学信息,2018,31(22):68.[doi:10.3969/j.issn.1006-1959.2018.22.019]
　HUANG Bing-wen.Comparison of Disease Progression and Prognostic Factors in Two Diagnostic Criteria for Type 2 Diabetic Nephropathy in China and the United States[J].Medical Information,2018,31(11):68.[doi:10.3969/j.issn.1006-1959.2018.22.019]
[2]陈晓霞,唐 勇,胡 庆,等.吗替麦考酚酯联合糖皮质激素治疗特发性膜性肾病的疗效观察[J].医学信息,2018,31(22):89.[doi:10.3969/j.issn.1006-1959.2018.22.024]
　CHEN Xiao-xia,TANG Yong,HU Qing,et al.Therapeutic Effect of Mycophenolate Mofetil Combined with Glucocorticoid on Idiopathic Membranous Nephropathy[J].Medical Information,2018,31(11):89.[doi:10.3969/j.issn.1006-1959.2018.22.024]
[3]高 彬,孙 娜,常文秀.慢性肾脏病患者血钾异常相关因素分析[J].医学信息,2019,32(22):91.[doi:10.3969/j.issn.1006-1959.2019.22.027]
　GAO Bin,SUN Na,CHANG Wen-xiu.Analysis of Related Factors of Serum Potassium Abnormality in Patients with Chronic Kidney Disease[J].Medical Information,2019,32(11):91.[doi:10.3969/j.issn.1006-1959.2019.22.027]
[4]伊学军,翟建新.胱抑素C检测及其在肾脏相关疾病中的应用[J].医学信息,2020,33(04):55.[doi:10.3969/j.issn.1006-1959.2020.04.017]
　YI Xue-jun,ZHAI Jian-xin.Cystatin C Detection and its Application in Kidney-related Diseases[J].Medical Information,2020,33(11):55.[doi:10.3969/j.issn.1006-1959.2020.04.017]
[5]袁 刚.特发性膜性肾病患者肾组织及血液中PLA2R抗体表达的检测及其意义[J].医学信息,2020,33(12):99.[doi:10.3969/j.issn.1006-1959.2020.12.029]
　YUAN Gang.Detection and Significance of PLA2R Antibody Expression in Renal Tissue and Blood of Patients with Idiopathic Membranous Nephropathy[J].Medical Information,2020,33(11):99.[doi:10.3969/j.issn.1006-1959.2020.12.029]
[6]鲍江波.雷公藤多苷和泼尼松片联合治疗特发性膜性肾病的有效性分析[J].医学信息,2020,33(14):157.[doi:10.3969/j.issn.1006-1959.2020.14.050]
　BAO Jiang-bo.Analysis of the Efficacy of Tripterygium Glycosides and Prednisone Tablets in the Treatment of Idiopathic Membranous Nephropathy[J].Medical Information,2020,33(11):157.[doi:10.3969/j.issn.1006-1959.2020.14.050]
[7]张国锐,贾 林,赵 丹,等.老年维持血液透析患者恶性肿瘤发病的相关因素分析[J].医学信息,2022,35(10):113.[doi:10.3969/j.issn.1006-1959.2022.10.027]
　ZHANG Guo-rui,JIA Lin,ZHAO Dan,et al.Analysis of Related Factors of Malignant Tumor in Elderly Maintenance Hemodialysis Patients[J].Medical Information,2022,35(11):113.[doi:10.3969/j.issn.1006-1959.2022.10.027]
[8]阎 丽,宋 迎.甲状腺激素与不同阶段2型糖尿病肾病的相关性研究[J].医学信息,2022,35(19):155.[doi:10.3969/j.issn.1006-1959.2022.19.045]
　YAN Li,SONG Ying.Study on the Correlation Between Thyroid Hormone and Different Stages of Type 2 Diabetic Nephropathy[J].Medical Information,2022,35(11):155.[doi:10.3969/j.issn.1006-1959.2022.19.045]
[9]陈 甜,付朝霞.中性粒细胞明胶酶相关脂质运载蛋白对早期糖尿病肾病的诊断价值[J].医学信息,2023,36(23):95.[doi:10.3969/j.issn.1006-1959.2023.23.024]
　CHEN Tian,FU Zhao-xia.Diagnostic Value of Neutrophil Gelatinase-associated Lipocalin in Early-stage Diabetic Nephropathy[J].Medical Information,2023,36(11):95.[doi:10.3969/j.issn.1006-1959.2023.23.024]

更新日期/Last Update: 1900-01-01